AltiBio, Inc. (AltiBio) was founded in early 2017 by a team with successful experience developing and commercializing orphan therapeutics. AltiBio currently has three projects in development: ATB223, ATB224, and ATB338, with two molecules, for one rare disease.
Proof of concept has been shown for all three projects and patent applications have been filed. Series A funding has also been completed. AltiBio now has the foundation to build a company through which significant therapeutics can be discovered, developed, and commercialized.